ANVS - Annovis Bio, Inc.
NYSE
->
Healthcare
->
Biotechnology
Berwyn,
United States
Type: Equity
ANVS price evolution
ANVS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4 | $3.14 | $5.75 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $14.36 | $5.05 | $7.81 | $10.21 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14.36 | $5.05 | $7.81 | $10.21 |
| Current liabilities | ||||
| Accounts payable | $4.1 | $3.39 | $4.11 | $1.29 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.39 | $4.06 | $4.87 | $4.28 |
| Long term debt | ||||
| Total noncurrent liabilities | $2.74 | $6.3 | $13.68 | |
| Total debt | ||||
| Total liabilities | $7.3 | $6.8 | $11.17 | $17.96 |
| Shareholders' equity | ||||
| Retained earnings | -$128.98 | -$116.35 | -$111.33 | -$110.26 |
| Other shareholder equity | ||||
| Total shareholder equity | -$1.75 | -$3.35 | -$7.75 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.75 | $28.38 | $45.69 | $8.07 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $10.21 | $36.02 | $46 | $8.12 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $10.21 | $36.02 | $46 | $8.12 |
| Current liabilities | ||||
| Accounts payable | $1.29 | $3.96 | $0.69 | $0.34 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.28 | $7.7 | $1.51 | $0.58 |
| Long term debt | ||||
| Total noncurrent liabilities | $13.68 | |||
| Total debt | ||||
| Total liabilities | $17.96 | $7.7 | $1.51 | $0.58 |
| Shareholders' equity | ||||
| Retained earnings | -$110.26 | -$54.05 | -$28.73 | -$14.24 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | -$7.75 | $28.32 | $44.49 | $7.54 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $5.79 | $6.51 | $8.9 | |
| Selling, general & administrative | $1.98 | $1.29 | $1.54 | |
| Total operating expenses | $7.76 | $7.81 | $10.44 | |
| Operating income | -$7.76 | -$7.81 | -$10.44 | |
| Income from continuing operations | ||||
| EBIT | -$5.02 | -$1.07 | -$22.21 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.02 | -$1.07 | -$22.21 | |
| Income (for common shares) | -$5.02 | -$1.07 | -$22.21 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $38.79 | $16.52 | $8.48 | |
| Selling, general & administrative | $6.24 | $9 | $6.06 | |
| Total operating expenses | $45.04 | $25.51 | $14.54 | $6.64 |
| Operating income | -$45.04 | -$25.51 | -$14.54 | -$6.64 |
| Income from continuing operations | ||||
| EBIT | -$56.2 | -$25.33 | -$14.49 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$56.2 | -$25.33 | -$14.49 | -$5.46 |
| Income (for common shares) | -$56.2 | -$25.33 | -$14.49 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5.02 | -$1.07 | -$22.21 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.6 | $0.36 | $0.88 | |
| Total cash flows from operations | -$3.38 | -$7.03 | -$9.36 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.24 | $4.42 | $8.76 | |
| Net borrowings | ||||
| Total cash flows from financing | $20.49 | $4.24 | $4.42 | $8.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $6.88 | $0.86 | -$2.62 | -$0.6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$56.2 | -$25.33 | -$14.49 | -$5.46 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.63 | $9.15 | $4.7 | |
| Total cash flows from operations | -$39.97 | -$17.31 | -$9.13 | -$3.97 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.34 | $0 | $46.74 | |
| Net borrowings | ||||
| Total cash flows from financing | $17.34 | $0 | $46.74 | $12.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.62 | -$17.31 | $37.61 | $8.07 |
News
Fundamentals
| Market cap | $27.90M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.28M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -2.32 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.66 |
| Quick ratio | N/A |